|本期目录/Table of Contents|

[1]吴亚松,马烨.HIV 耐药评估和预防策略[J].传染病信息,2017,06:351-354.
 WU Ya-song*,MA Ye.HIV drug resistance assessment and prevention strategy[J].Infectious Disease Information,2017,06:351-354.
点击复制

HIV 耐药评估和预防策略(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2017年06期
页码:
351-354
栏目:
专题综述
出版日期:
2017-12-20

文章信息/Info

Title:
HIV drug resistance assessment and prevention strategy
作者:
吴亚松马烨
102206 北京,中国疾病预防控制中心性病艾滋病预防控制中心治疗与关怀室(吴亚松、马烨)
Author(s):
WU Ya-song* MA Ye
Division of Treatment and Care, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control andPrevention, Beijing 102206, China
关键词:
HIV耐药抗病毒治疗评估
Keywords:
HIV drug resistance antiretroviral therapy assessment
分类号:
R512.91;R915
DOI:
10.3969/j.issn.1007-8134.2017.06.009
文献标识码:
A
摘要:
HIV 耐药会影响抗病毒治疗的长期疗效,使得艾滋病流行结束于2030 年的目标难以实现。不同国家采用不同策略来预防和评估HIV 耐药的产生和传播。目前,高收入国家对HIV 感染者进行个体耐药检测。多数中低收入国家采用WHO 提出的群体监测策略,监测耐药早期预警指标,评估治疗人群获得性耐药,监测治疗前耐药、传播性耐药及18 月龄以下儿童耐药等措施。我国采用HIV 耐药个体检测和群体监测相结合的防控策略。
Abstract:
HIV drug resistance (HIVDR) can threat the long-term effects of antiretroviral therapy (ART), and jeopardize the goalof eliminating HIV in 2030. Different strategies are adopted in different countries to prevent and assess the emergence and transmissionof HIVDR. In high income countries, the HIVDR testing for individual with HIV is used at present. In most of middle- and lowincomecountries, population level strategies are recommended, including monitoring of HIVDR early warning indicators, surveillanceof acquired drug resistance in populations receiving ART, surveillance of pretreatment drug resistance, surveillance of transmitted drugresistances, and surveillance of HIVDR among treatment-naive infant less than 18 months of age. The combination of individual HIVDRtesting and population-level surveys are taken as the prevention strategy in China.

参考文献/References

[1] UNAIDS. Global leaders commit to ending the AIDS epidemic incities by 2030[EB/OL].
[2016-10-21]. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/july/20140720cities.
[2] UNAIDS. 90-90-90 - An ambitious treatment target to help endthe AIDS epidemic[EB/OL].
[2017-11-20]. http://www.unaids.org/en/resources/documents/2017/90-90-90.
[3] World Health Organization. Guideline on when to startantiretroviral therapy and on pre-exposure prophylaxis for HIV[M].Geneva:World Health Organization, 2015.
[4] World Health Organization. Consolidated guidelines on the useof antiretroviral drugs for treating and preventing HIV infection:recommendations for a public health approach-second edition 2016 [M]. Geneva:World Health Organization, 2016.
[5] UNAIDS. Fact sheet - Latest global and regional statistics on thestatus of the AIDS epidemic[EB/OL].
[2017-11-20]. http://www.unaids.org/en/resources/documents/2017/UNAIDS_FactSheet.
[6] Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation ofantiretroviral treatment and increased treatment coverage on HIVrelatedmortality in China: a national observational cohort study[J].Lancet Infect Dis, 2011, 11(7):516-524.
[7] Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality ofHIV-infected patients initiating antiretroviral therapy: comparisonwith mortality in general population in China, 2003-2009[J]. JAcquir Immune Defic Syndr, 2013, 63(5):e150-e157.
[8] Jia Z, Mao Y, Zhang F, et al. Antiretroviral therapy to preventHIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study[J]. Lancet, 2013,382(9899):1195-1203.
[9] 吴亚松,吴昊. HIV 的耐药研究进展[J]. 国外医学(病毒学分册),2004,11(6):190.
[10] Godfrey C, Bobkova M, Boucher C, et al. Regional challenges in theprevention of human immunodeficiency virus drug resistance[J].J Infect Dis, 2017, 216(suppl 9):S816-S819.
[11] 李敬云. HIV 耐药检测的临床应用[J]. 传染病信息,2012,25(6):325-327,338.
[12] 贺健梅,邹潇白,陈曦,等. 超深度焦磷酸测序技术用于HIV-1 RT 基因区原发性耐药突变的研究[J]. 中华流行病学杂志,2014,(10):1142-1145.
[13] Bennett DE, Camacho RJ, Otelea D, et al. Drug resistancemutations for surveillance of transmitted HIV-1 drug-resistance:2009 update[J]. PLoS One, 2009, 4(3):e4724.
[14] Department of Health and Human Services. Guidelines for the useof antiretroviral agents in adults and adolescents living with HIV. [EB/OL].
[2017-11-5]. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0.
[15] European AIDS Clinical Society. EACS Guidelines version 9.0 [EB/OL].
[2017-11-6]. http://www.eacsociety.org/files/guidelines_9.0-english.pdf.
[16] British HIV Association. British HIV Association guidelines forthe routine investigation and monitoring of HIV-1-positive adults2016[EB/OL].
[2017-4-26]. http://www.bhiva.org/monitoringguidelines.aspx.
[17] Churchill D, Waters L, Ahmed N, et al. British HIV Associationguidelines for the treatment of HIV-1-positive adults withantiretroviral therapy 2015[J]. HIV Med, 2016, 17(Suppl 4):s2-s104.
[18] Bennett DE, Bertagnolio S, Sutherland D, et al. The World HealthOrganization’s global strategy for prevention and assessment of HIVdrug resistance[J]. Antivir Ther, 2008, 13(Suppl 2):1-13.
[19] Jordan MR, Bennett DE, Bertagnolio S, et al. World HealthOrganization surveys to monitor HIV drug resistance preventionand associated factors in sentinel antiretroviral treatment sites[J].Antivir Ther, 2008, 13(Suppl 2):15-23.
[20] Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations forsurveillance of transmitted HIV drug resistance in countries scalingup antiretroviral treatment[J]. Antivir Ther, 2008, 13(Suppl2):25-36.
[21] Myatt M, Bennett DE. A novel sequential sampling techniquefor the surveillance of transmitted HIV drug resistance by crosssectionalsurvey for use in low resource settings[J]. Antivir Ther,2008, 13(Suppl 2):37-48.
[22] Shafer RW, Rhee SY, Bennett DE. Consensus drug resistancemutations for epidemiological surveillance: basic principles andpotential controversies[J]. Antivir Ther, 2008, 13(Suppl 2):59-68.
[23] World Health Organization. Global strategy for the surveillance andmonitoring of HIV drug resistance 2012[EB/OL].
[2012-12-27]. http://www.who.int/hiv/pub/drugresistance/drug_resistance_strategy/en/.
[24] Phillips AN, Cambiano V, Miners A, et al. Effectiveness andcost-effectiveness of potential responses to future high levelsof transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economicanalysis[J]. Lancet HIV, 2014, 1(2):e85-e93.
[25] World Health Organization. Surveillance of HIV drug resistancein adults initiating antiretroviral therapy (Pre-treatment HIV drugresistance)[EB/OL].
[2017-5-8]. http://apps.who.int/iris/bitstream/10665/112802/1/9789241507196_eng.pdf?ua=1.
[26] World Health Organization. Surveillance of HIV drug resistance inadults receiving ART[EB/OL].
[2016-1-13]. http://apps.who.int/iris/bitstream/10665/112801/1/9789241507073_eng.pdf?ua=1.
[27] World Health Organization. HIV drug resistance surveillanceguidance: updated 2015[EB/OL].
[2017-10-29]. http://apps.who.int/iris/bitstream/10665/204471/1/9789241510097_eng.pdf?ua=1.
[28] . World Health Organization. Global action plan on HIV drugresistance 2017–2021[EB/OL].
[2017-10-16]. http://www.who.int/hiv/drugresistance/hivdr_darft_gap.pdf?ua=1.
[29] Ma Y, Zhang F, Li H, et al. Monitoring HIV drug resistanceusing early warning indicators in China: results from a pilotsurvey conducted in 2008[J]. Clin Infect Dis, 2012, 54(Suppl4):S300-S302.
[30] 焦丽燕,鲍作义,李韩平,等. 体外无药物选择压力条件下HIV-1耐药基因突变的演变[J].中华微生物学和免疫学杂志,2010,30(5):431-437.
[31] 陈曦,邢辉,贺健梅,等. 湖南省HIV-1 耐药警戒线调查[J].中华流行病学杂志,2008,29(8):787-789.
[32] 黑发欣,李洋,廖玲洁,等. 2008 年北京市HIV-1 耐药株传播调查[J]. 中华微生物学和免疫学杂志,2009,29(6):499-502.
[33] 马艳玲,王继宝,邢辉,等. 云南省德宏州2013 年HIV-1 耐药毒株传播警戒线调查结果分析[J]. 中华流行病学杂志,2015,36(6):584-588.
[34] Dai L, Li N, Wei F, et al. Transmitted antiretroviral drug resistancein the men who have sex with men HIV patient cohort, Beijing,China, 2008-2011[J]. 2014, 27(8):392-397.
[35] Wang X, Wu Y, Mao L, et al. Targeting HIV prevention based onmolecular epidemiology among deeply sampled subnetworks of menwho have sex with men[J]. Clin Infect Dis, 2015, 61(9):1462-1468.
[36] 李扬,邢辉. 未治疗艾滋病患者中HIV耐药株的传播研究[J].中华微生物学和免疫学杂志,2016,36(7):540-544.
[37] 孙晓光,于海英,苏生利,等. 山东省2013—2015 年新发现未治疗HIV-1 感染者耐药毒株传播警戒线调查[J]. 中华预防医学杂志,2017,51(7):604-609.
[38] 张旻,尚红,韩晓旭,等. 中国东北地区未经抗病毒治疗ART 的HIV/AIDS 患者HIV 毒株的耐药基因变异研究[J].中华微生物学和免疫学杂志,2004,24(11):850-854.
[39] Su Y, Zhang F, Liu H, et al. The prevalence of HIV-1 drugresistance among antiretroviral treatment naive individualsin mainland China: a meta-analysis[J]. PLoS One, 2014,9(10):e110652.
[40] Liu J, Wu Y, Yang W, et al. Population-based humanimmunodeficiency virus 1 drug resistance profiles amongindividuals who experienced virological failure to first-lineantiretroviral therapy in Henan, China during 2010-2011[J].AIDS Res Ther, 2015, 12:22.
[41] 梁欣,彭晓霞. 中国HIV 感染者和艾滋病患者抗逆转录病毒治疗后耐药情况的Meta 分析[J]. 国际流行病学传染病学杂志,2016,43(3):197-202.
[42] World Health Organization. WHO HIV drug resistance report2012[EB/OL].
[2017-11-7]. http://www.who.int/hiv/pub/drugresistance/report2012/en/.
[43] World Health Organization. HIV drug resistance report 2017[EB/OL].
[2017-8-27]. http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/.

备注/Memo

备注/Memo:
[基金项目] 中美艾滋病合作项目(2017-2018-7.12)
[通信作者] 吴亚松,E-mail: wuys@chinaaids.cn
更新日期/Last Update: 2017-12-20